WO2016122226A2 - A pharmaceutical composition for treating gastrointestinal diseases - Google Patents

A pharmaceutical composition for treating gastrointestinal diseases Download PDF

Info

Publication number
WO2016122226A2
WO2016122226A2 PCT/KR2016/000935 KR2016000935W WO2016122226A2 WO 2016122226 A2 WO2016122226 A2 WO 2016122226A2 KR 2016000935 W KR2016000935 W KR 2016000935W WO 2016122226 A2 WO2016122226 A2 WO 2016122226A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
particle size
sucralfate
bismuth subcitrate
composition according
Prior art date
Application number
PCT/KR2016/000935
Other languages
French (fr)
Other versions
WO2016122226A3 (en
Inventor
Young Ho Cho
Jun Woo Lee
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016122226(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2017540683A priority Critical patent/JP6419347B2/en
Priority to BR112017013857-3A priority patent/BR112017013857B1/en
Priority to UAA201707833A priority patent/UA116517C2/en
Priority to EP16743704.5A priority patent/EP3250199A4/en
Priority to MX2017007567A priority patent/MX2017007567A/en
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Priority to CN201680007680.7A priority patent/CN107205947B/en
Priority to EA201791458A priority patent/EA032385B9/en
Priority to MYPI2017702737A priority patent/MY195824A/en
Publication of WO2016122226A2 publication Critical patent/WO2016122226A2/en
Publication of WO2016122226A3 publication Critical patent/WO2016122226A3/en
Priority to CONC2017/0006222A priority patent/CO2017006222A2/en
Priority to PH12017550051A priority patent/PH12017550051A1/en
Priority to SA517382016A priority patent/SA517382016B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients.
  • Ranitidine is a drug of suppressing gastric acid production through H2 receptor blocking and is being used to treat stomach ulcers or reflux esophagitis.
  • the fact that, when ranitidine is administered together with bismuth subcitrate and sucralfate as a combination therapy, it shows an excellent therapeutic effect for stomach ulcers and duodenal ulcer has been known (Korean Laid-open Patent No. 1997-006083, Patent Literature 1). Therefore, a combination drug comprising these three drugs as active ingredients is currently commercially available.
  • ranitidine has strong hygroscopicity, causes a moisture absorption while being stored, and causes a change in a weight and a property of a tablet (PDA J. Pharm. Sci. Tech. 2009 May-Jun:63(3):223-33). Therefore, it has a problem in that a disintegration time of a tablet is changed.
  • ranitidine when ranitidine is mixed with bismuth subcitrate, there is a problem in that a physical property of ranitidine is changed due to bismuth subcitrate.
  • Patent Literature 1 discloses a method in which ranitidine is prepared as a core tablet, and bismuth subcitrate and sucralfate are mixed to prepare a tablet-within-a-tablet containing the core tablet.
  • Patent Literature 2 discloses a method in which a problem in that, when ranitidine is released in a stomach, ranitidine is adsorbed to sucralfate and an absorption rate of ranitidine decreases was identified, accordingly a core tablet containing ranitidine is coated with a film-forming composition and then mixed with bismuth subcitrate and sucralfate to prepare a tablet-within-a-tablet.
  • a combination drug that can address the following problems: 1) a problem of hygroscopicity of ranitidine itself, 2) a problem of a decrease in stability of ranitidine according to mixing with bismuth subcitrate, and 3) a problem of a decrease in a drug absorption rate due to mixing of three drugs when a combination drug of ranitidine, bismuth subcitrate and sucralfate is prepared. Further, it is necessary to prepare a combination drug than have simple preparation process, is more comfortable for a patient to swallow, and have excellent bioavailability.
  • Patent Literature 1 Korean Laid-open Patent No.1997-006083
  • Patent Literature 2 Korea Patent No. 10-0453179
  • Non-Patent Literature 1 PDA J. Pharm. Sci. Tech. 2009 May-Jun:63(3):223-33
  • the present invention provides a combination drug capable of addressing problems with regard to formulation stability and bioavailability in a combination drug of ranitidine, bismuth subcitrate and sucralfate, and that has a simple preparation process and more comfortable for a patient to swallow.
  • a grinder or a mesh for each type was used to classify sucralfate and bismuth subcitrate for each particle size, a particle size was measured, sucralfate and bismuth subcitrate classified for each size were used and mixed with ranitidine, and then a moisture content, formulation stability and bioavailability of ranitidine were observed. As a result, it was confirmed that a moisture content of ranitidine was suppressed in a specific particle size range of sucralfate and bismuth subcitrate, formulation stability was maintained, and drug bioavailability was excellent. Then, the size was selected as an optimum particle size.
  • the present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients, and satisfies at least one of the following conditions:
  • sucralfate has an average particle size of 1 to 25 ⁇ m
  • bismuth subcitrate has an average particle size of 5 to 90 ⁇ m.
  • the sucralfate may have an average particle size of 1 to 25 ⁇ m, for example, 1 to 20 ⁇ m, 2 to 25 ⁇ m, 2 to 20 ⁇ m, 2 to 15 ⁇ m, 3 to 15 ⁇ m, 2 to 10 ⁇ m, 3 to 10 ⁇ m, 3 to 8 ⁇ m, 4 to 10 ⁇ m, or 4 to 8 ⁇ m.
  • the bismuth subcitrate may have an average particle size of 5 to 90 ⁇ m, for example, 5 to 80 ⁇ m, 5 to 75 ⁇ m, 5 to 70 ⁇ m, 10 to 75 ⁇ m, 10 to 60 ⁇ m, 10 to 50 ⁇ m, 15 to 75 ⁇ m, 20 to 75 ⁇ m, 25 to 70 ⁇ m, 25 to 65 ⁇ m, 25 to 60 ⁇ m, 25 to 55 ⁇ m, or 25 to 50 ⁇ m.
  • the sucralfate may have an average particle size of 2 to 25 ⁇ m, or 2 to 10 ⁇ m.
  • the bismuth subcitrate may have an average particle size of 5 to 75 ⁇ m, 25 to 70 ⁇ m, or 25 to 50 ⁇ m.
  • the sucralfate may have an average particle size of 1 to 25 ⁇ m
  • the bismuth subcitrate may have an average particle size of 5 to 90 ⁇ m.
  • sucralfate may have an average particle size of 2 to 25 ⁇ m
  • bismuth subcitrate may have an average particle size of 5 to 75 ⁇ m.
  • the sucralfate may have an average particle size of 2 to 10 ⁇ m
  • the bismuth subcitrate may have an average particle size of 25 to 70 ⁇ m.
  • sucralfate and bismuth subcitrate having an average particle size within the above-exemplified range are combined and used, it is possible to obtain a pharmaceutical composition that is an object of the present invention.
  • the average particle size is an average of a volume or a mass, and refers to a volume weighted Mean D[4,3] value with respect to a weight of a distribution.
  • a general mill capable of micronizing particles such as a Z-mill, a hammer mill, a ball mill, a fluid energy mill or the like may be used for grinding.
  • a sieve method that is performed using a sieve or a size classification method such as air current classification is used, it is possible to subdivide a particle size of a drug.
  • a method of regulating a desired particle size is well-known in the related art. For example, the following document: [Pharmaceutical dosage forms: volume 2, 2nd edition, Ed.: H.A.Lieberman, L.Lachman, J.B.Schwartz (Chapter 3: SIZE REDUCTION)] is referenced to.
  • d(10) represents a diameter of a particle at a point at which particle sizes of a drug accumulate in ascending order and the result reaches 10%.
  • d(50) represents a diameter of a particle at a point at which particle sizes of a drug accumulate in ascending order and the result reaches 50%.
  • d(90) represents a diameter of a particle at a point at which particle sizes of a drug accumulate in ascending order and the result reaches 90%.
  • d(X) is alternatively represented as d(0.X), and d(X) and d(0.X) are interchangeable.
  • d(50) is represented as d(0.5)
  • d(10) and d(90) are represented as d(0.1) and d(0.9), respectively.
  • a number, a volume, or a weight that is used as a reference when the particle size distribution d(X) represents a percent with respect to total accumulated particles is changed according to a method that is used to measure a particle size distribution.
  • the method of measuring the particle size distribution and a type of % related thereto are known in the related art.
  • an X value of d(X) represents a percent calculated according to a volume average.
  • the particle size distribution measurement result obtained by a specific method may have a correlation with results obtained from other techniques based on experiences through general experiments.
  • a volume average particle size is provided to correspond to a volume of a particle, which corresponds to a weight average particle size when a density is constant.
  • a commercially available device using a laser diffraction and scattering method based on a Mie theory may be used.
  • a commercially available device such as a Mastersizer laser diffraction device of Malvern Instruments may be used for measurement. This device is used to obtain a particle diameter distribution such that, when a helium-neon laser beam is emitted toward or a blue light emitting diode emits light toward particles, scattering is caused, a light scattering pattern is shown in a detector, and this light scattering pattern is analyzed according to the Mie theory.
  • Any of dry and wet methods may be used as the measurement method, but results measured by the wet method are shown in the following examples.
  • the pharmaceutical composition of the present invention may have a particle size distribution of sucralfate that additionally satisfies at least one of the following conditions.
  • d(10) is 1 to 10 ⁇ m
  • d(50) is 3 to 25 ⁇ m
  • d(90) is 5 to 50 ⁇ m.
  • the pharmaceutical composition of the present invention may have a particle size distribution of bismuth subcitrate that additionally satisfies at least one of the following conditions.
  • d(50) is 20 to 70 ⁇ m
  • d(90) is 40 to 130 ⁇ m.
  • the pharmaceutical composition of the present invention may have a particle size distribution of sucralfate that additionally satisfies at least one of the following conditions:
  • d(10) is 1 to 10 ⁇ m
  • d(50) is 3 to 25 ⁇ m
  • d(90) is 5 to 50 ⁇ m
  • a particle size distribution of bismuth subcitrate may satisfy at least one of the following conditions:
  • d(50) is 20 to 70 ⁇ m
  • d(90) is 40 to 130 ⁇ m.
  • a particle size of ranitidine included in the pharmaceutical composition of the present invention is not particularly limited.
  • the present invention also provides a pharmaceutical composition in which sucralfate and bismuth subcitrate whose average particle size or particle size distribution are within the above range, and sucralfate has a dissolution rate whose level is equivalent to a dissolution rate of sucralfate of Albis TM Tablet.
  • sucralfate and bismuth subcitrate whose average particle size or particle size distribution are within the above range
  • sucralfate has a dissolution rate whose level is equivalent to a dissolution rate of sucralfate of Albis TM Tablet.
  • the guidelines for drug equivalence test control may be used to determine whether the dissolution rate shows an equivalent level.
  • the present invention also provides a pharmaceutical composition in which sucralfate and bismuth subcitrate whose average particle sizes or particle size distributions are within the above range, and ranitidine and bismuth subcitrate show an area under the concentration-time curve (AUC) and a maximum observed plasma concentration (C max ) of a bioequivalence level, compared to Albis TM Tablet having the same active ingredient dose.
  • drug equivalence criteria may be used to determine whether the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (C max ) show a bioequivalence level.
  • AUC area under the concentration-time curve
  • C max maximum observed plasma concentration
  • contents of ranitidine, sucralfate and bismuth subcitrate which are active ingredients of the pharmaceutical composition of the present invention, may be included at a composition ratio of 1 to 2 parts by weight of ranitidine, 6 to 12 parts by weight of sucralfate, and 2 to 4 parts by weight of bismuth subcitrate to be pharmacologically effectively functioned.
  • the pharmaceutical composition of the present invention is preferably prepared to comprise ranitidine at 50 to 300 mg, sucralfate at 240 to 1200 mg, and bismuth subcitrate at 80 to 400 mg, and particularly preferably prepared to include ranitidine at 50 to 150 mg, sucralfate at 240 to 600 mg, and bismuth subcitrate at 80 to 200 mg.
  • the pharmaceutical composition of the present invention comprises at least one excipient other than the active ingredients.
  • a diluent increases a volume of a solid pharmaceutical composition, and enables for a patient and a caregiver to handle more easily a pharmaceutical dosage form including the composition.
  • Exemplary diluents for the solid composition include microcrystalline cellulose (for example, Avicel ® ), microfine cellulose, lactose, a starch, a pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrate, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, a magnesium oxide, maltodextrin, mannitol a polymethacrylate (for example, Eudragit ® ), calcium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
  • microcrystalline cellulose for example, Avicel ®
  • microfine cellulose for example, lactose, a starch, a pregelatinized starch
  • the solid pharmaceutical composition compressed in a dosage form such as a tablet may comprise an excipient that helps the active ingredient to be bound to another excipient after compression.
  • Binders for the solid pharmaceutical composition include acacia, alginic acid, a carbomer (for example, a carbopol), sodium carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxy ethylcellulose, hydroxypropyl cellulose (for example, Klucel ® ), hydroxypropylmethylcellulose (for example, Methocel ® ), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, a polymethacrylate, povidone (for example, Kollidon ® and Plasdone ® ), a pregelatinized starch, sodium alginate and a starch.
  • a carbomer for example, a carbopol
  • sodium carboxymethylcellulose dextrin
  • ethylcellulose gelatin
  • the disintegrant includes hydroxypropylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium (for example, Ac-Di-Sol ® , Primellose ® ), microcrystalline cellulose, methylcellulose, powdered cellulose, colloidal silicon dioxide, croscarmellose sodium, crospovidone (for example, Kollidon ® and Polyplasdone ® ), guar gum, magnesium aluminum silicate, polacrilin potassium, a pregelatinized starch, alginic acid, sodium alginate, sodium starch glycolate (for example, Explotab ® ) and a starch.
  • hydroxypropylcellulose carboxymethylcellulose calcium, carboxymethylcellulose sodium (for example, Ac-Di-Sol ® , Primellose ® ), microcrystalline cellulose, methylcellulose, powdered cellulose, colloidal silicon dioxide, croscarmellose sodium, crospovidone (for example, Kollidon ® and Polyplasdone ® ), guar gum,
  • a powder composition When a powder composition is compressed to prepare a dosage form such as a tablet, the composition receives a pressure from a punch and a dye. Some excipients and active ingredients tend to adhere to a surface of the punch and the dye, which may cause pitting and other surface irregularity in products. In order to decrease adhesiveness and easily extract a product material from the dye, a lubricant may be added to the composition.
  • the lubricant includes stearate salts such as magnesium stearate, calcium stearate, aluminum stearate and zinc stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, a polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, talc and the like.
  • stearate salts such as magnesium stearate, calcium stearate, aluminum stearate and zinc stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, a polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, talc and the like.
  • storage and chelate formulations such as alcohol, sodium benzoate, butylated hydroxytoluene, butylated hydroxyanisole and ethylenediaminetetraacetic acid may be added at a safe intake level.
  • the pharmaceutical composition of the present invention is not limited thereto, but may be formulated as a tablet.
  • the pharmaceutical composition of the present invention may be formulated as a matrix tablet.
  • the pharmaceutical composition of the present invention is not formulated as a tablet-within-a-tablet containing a core tablet, but is formulated as a matrix tablet after particle sizes of sucralfate and bismuth subcitrate are controlled. Nevertheless, it was confirmed that all problems of a combination formulation in the related art were solved.
  • a tablet comprising the pharmaceutical composition according to the present invention may be additionally coated with a coating agent.
  • An embodiment of the present invention provides a tablet in which an uncoated tablet comprising ranitidine, sucralfate, and bismuth subcitrate as active ingredients is coated with a polyvinyl alcohol.
  • Granules are prepared at a mixing ratio of 150:600:200 of ranitidine, sucralfate and bismuth.
  • a binder hydroxypropylmethylcellulose, hydroxypropylcellulose, a polyvinylpyrrolidone and the like may be used as other binders.
  • drying is preferably performed at a temperature of 30 to 60 °C such that a moisture content of a granule composition becomes 11% or less with respect to a total weight, and drying is most preferably performed at a temperature of 50 °C.
  • the present invention provides a method of treating gastrointestinal diseases comprising administering the pharmaceutical composition comprising ranitidine, sucralfate and bismuth subcitrate having the above-exemplified particle size range as active ingredients to a subject in need thereof, and a use of the composition comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients to prepare a drug for treating gastrointestinal diseases.
  • gastrointestinal diseases include all symptoms or diseases such as inflammation and ulcer that occur in a digestive organ.
  • gastrointestinal diseases include stomach ulcers, gastritis, duodenal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, medication before anesthesia (prevention Mendelson's syndrome), post-op ulcer, and gastroduodenal ulcer due to nonsteroidal anti-inflammatory drugs (NSAIDs), but the present invention is not limited thereto.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • the term "subject" refers to a warm-blooded animal such as a mammal suffering from specific diseases, disorders or diseases, and includes, for example, a human, an orangutan, a chimpanzee, a mouse, a rat, a dog, a cow, a chicken, a pig, a goat, a sheep and the like, but the present invention is not limited thereto.
  • treatment includes alleviating symptoms, temporarily or permanently removing causes of symptoms, prevention or slowdown of occurrence of symptoms and progress of diseases, disorders or illness, but the present invention is not limited thereto.
  • an effective dose of the active ingredient of the pharmaceutical composition of the present invention refers to an amount that is necessary to treat diseases. Therefore, the effective dose may be regulated according to various factors such as type of disease, severity of disease, type and contents of an active ingredient and other components contained in the composition, types of dosage forms, a patient's age, weight, general health condition, and gender, diet, an administration time, an administration route, a releasing rate of the composition, a treatment period, and a drug used at the same time.
  • the pharmaceutical composition of the present invention may be administered once to three times a day, and a dose of 50 to 150 mg based on ranitidine may be administered once, but the present invention is not limited thereto.
  • a combination drug that can address problems of hygroscopicity of ranitidine and formulation stability and has a simple preparation process and excellent bioavailability, by controlling particle sizes of sucralfate and bismuth subcitrate when the combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared.
  • FIGS. 1 and 2 show change of average concentration of bismuth subcitrate in plasma of subjects to which tablets of Preparation Examples 12, 15 and 16 and Preparation Examples 14 and 17 are administered.
  • FIG. 2 shows the enlarged FIG. 1.
  • FIGS. 3 to 5 show change of average concentration of ranitidine in plasma of subjects to which tablets of Preparation Examples 12, 15 and 16 are administered.
  • the raw material particle size was measured using a particle size measurement device (Malvern Mastersizer 2000/Hydro S) according to a wet method under the following conditions.
  • Sucralfate and bismuth subcitrate were micronized using the Z-mill and the grinder or using a mesh in order to regulate particle sizes.
  • sucralfate and bismuth subcitrate were classified as sucralfates 1 to 6 and bismuth subcitrates 1 to 5, and described in the following Tables 2 and 3.
  • a formulation comprising ranitidine, sucralfate and bismuth subcitrate having different raw material particle size combinations was prepared to select a particle size of a drug that can ensure formulation stability, and an appropriate dissolution rate and bioavailability of the drug.
  • Composition (wt%) of tablet comprising ranitidine, sucralfate and bismuth subcitrate Classification Content Ranitidine 12.2 Sucralfate 49.0 Bismuth subcitrate 16.3 Microcrystalline cellulose 13.0 Hydroxypropylcellulose 2.0 Croscarmellose sodium 5.0 Magnesium stearate 2.5 Total 100.0
  • dry granules or wet granules according to a general method were prepared using purified water (or a mixed solvent of purified water and ethanol), dried at 50 °C, and then established as an 18 mesh. Then, the prepared granules were tableted and coated to prepare a matrix tablet. Coating was performed with 3% PVA. Finally, a yellowish green rectangular film-coated tablet was obtained.
  • the tablets of Preparation Examples 1 to 6 were used to perform the comparison dissolution test of sucralfate. Since sucralfate is not absorbed in vivo, the bioequivalence test was not performed, but a comparison dissolution result was alternatively used.
  • Albis TM Tablet commercially available from Daewoong pharmaceutical Co., Ltd.
  • the comparison dissolution test was performed according to Article 3, Section 1, No 1 (the guidelines for drug equivalence test control). A dissolution solution having a pH of 1.2 was used. According to the Korean Pharmacopeia Guideline of dissolution testing (the second method (paddle method)), an HPLC method was performed at a dissolution solution temperature of 37 ⁇ 0.5 °C and 50 rpm for 2 hours.
  • sucralfates 4 to 6 of Table 2 were preferably used as sucralfate. Therefore, a particle size of sucralfate was fixed to a particle size of "sucralfate 6" and then a particle size of bismuth subcitrate was regulated to evaluate stability of a tablet according to the particle size of bismuth.
  • ranitidine, sucralfate and bismuth subcitrate were prepared to dry granules or wet granules according to a general method using purified water (or a mixed solvent of purified water and ethanol), dried at 50 °C and then established as an 18 mesh. Then, the prepared granules were tableted and prepared as a matrix tablet, and room temperature stability was evaluated.
  • PVA was selected as the coating agent, and the uncoated tablets of Preparation Examples 7, 8, 10, and 11 were coated with 3 wt% PVA to prepare coated tablets of Preparation Examples 14, 15, 16, and 17. Then, these coated tablets were used to perform the following experimental examples.
  • the coated tablets of Preparation Examples 12, 14, 15, 16 and 17 were used to perform a moisture content test as follows. The test was performed at room temperature for 6 months. In order to measure a moisture content, a Karl Fisher method among general test methods according to the Korean Pharmacopeia Guideline was used as a moisture measurement method. Using the fact that water is quantitatively reacted with iodine and sulfur dioxide in the presence of low level alcohol such as methanol and an organic base such as pyridine, methanol for moisture measurement was used as a reagent used for a moisture measurement method. A sample was obtained by grinding a tablet and about 200 mg thereof was used for the test.
  • Moisture content test results of coated tablets Test item Classification Criteria Initial Room temperature stability 1 month 3 months 6 months Moisture content Preparation Example 12 11% or less 9.16% 9.11% 9.23% 9.30% Preparation Example 14 9.17% 10.05% 10.92% - Preparation Example 15 10.22% 9.80% 9.97% 10.11% Preparation Example 16 8.49% 8.88% 8.67% 8.90% Preparation Example 17 9.35% 10.01% 10.75% -
  • tablets of Preparation Examples 12, 15 and 16 were appropriate for moisture content criteria.
  • the tablets of Preparation Examples 14 and 17 had an inappropriate property in the room temperature stability test for 6 months, and thus an additional moisture test was not performed. Based on such results, it was confirmed that a moisture content of ranitidine was suppressed due to particle sizes of sucralfate and bismuth subcitrate, and a more excellent stability of a product through PVA coating can be confirmed.
  • the coated tablets of Preparation Examples 12, 14, 15, 16 and 17 were used to perform a PK test on healthy subjects. With respect to log-transformed values of two comparison evaluation items of AUC and C max , analysis of variance was performed with bismuth subcitrate and ranitidine.
  • Albis TM Tablet (commercially available from Daewoong pharmaceutical Co., Ltd.) was used as the reference drug.
  • FIGS. 1 and 2 are comprehensive graphs that statistically show bioavailability parameters of the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (C max ) of bismuth subcitrate obtained from blood drug concentration data of subjects to which the tablets of Preparation Example 12, 14, 15, 16 and 17 were administered.
  • FIGS. 3 to 5 are graphs that statistically show bioavailability parameters of the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (C max ) of ranitidine obtained from blood drug concentration data of subjects to which the tablets of Preparation Examples 12, 15 and 16 were administered.
  • PK test results of the tablet of Preparation Example 12 were compared with PK test results of the reference drug.
  • AUC was 0.8749 to 1.1967
  • C max was 0.8681 to 1.12342. Therefore, it was confirmed that PK was equivalent.
  • ranitidine AUC was 0.9282 to 1.1213, C max was 0.9282 to 1.1539, and thus it was also equivalent.
  • the tablets of Preparation Examples 12, 15 and 16 suppressed a moisture content of ranitidine by appropriately regulating particle sizes of sucralfate and bismuth subcitrate and can be used as a combination drug of suppressing a change in a physical property due to drug mixing, and providing excellent bioavailability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients and a preparation method thereof. According to the present invention, when a combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared, it is possible to address a hygroscopicity problem of ranitidine and increase formulation stability and drug bioavailability by controlling particle sizes of sucralfate and bismuth subcitrate.

Description

A PHARMACEUTICAL COMPOSITION FOR TREATING GASTROINTESTINAL DISEASES
The present invention relates to a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients.
Ranitidine is a drug of suppressing gastric acid production through H2 receptor blocking and is being used to treat stomach ulcers or reflux esophagitis. The fact that, when ranitidine is administered together with bismuth subcitrate and sucralfate as a combination therapy, it shows an excellent therapeutic effect for stomach ulcers and duodenal ulcer has been known (Korean Laid-open Patent No. 1997-006083, Patent Literature 1). Therefore, a combination drug comprising these three drugs as active ingredients is currently commercially available.
However, ranitidine has strong hygroscopicity, causes a moisture absorption while being stored, and causes a change in a weight and a property of a tablet (PDA J. Pharm. Sci. Tech. 2009 May-Jun:63(3):223-33). Therefore, it has a problem in that a disintegration time of a tablet is changed.
Also, when ranitidine is mixed with bismuth subcitrate, there is a problem in that a physical property of ranitidine is changed due to bismuth subcitrate.
Therefore, Patent Literature 1 discloses a method in which ranitidine is prepared as a core tablet, and bismuth subcitrate and sucralfate are mixed to prepare a tablet-within-a-tablet containing the core tablet. Also, Patent Literature 2 (Korea Patent No. 10-0453179) discloses a method in which a problem in that, when ranitidine is released in a stomach, ranitidine is adsorbed to sucralfate and an absorption rate of ranitidine decreases was identified, accordingly a core tablet containing ranitidine is coated with a film-forming composition and then mixed with bismuth subcitrate and sucralfate to prepare a tablet-within-a-tablet. However, there is a problem in that, when a core tablet containing ranitidine is coated with a film to prepare a tablet-within-a-tablet, a preparation process becomes complex and a preparation cost increases. Also, since the tablet-within-a-tablet has a larger tablet size than a matrix tablet having the same dose, if a drug dose increases, the tablet size excessively increases and it is less comfortable for a patient to swallow.
Therefore, it is necessary to prepare a combination drug that can address the following problems: 1) a problem of hygroscopicity of ranitidine itself, 2) a problem of a decrease in stability of ranitidine according to mixing with bismuth subcitrate, and 3) a problem of a decrease in a drug absorption rate due to mixing of three drugs when a combination drug of ranitidine, bismuth subcitrate and sucralfate is prepared. Further, it is necessary to prepare a combination drug than have simple preparation process, is more comfortable for a patient to swallow, and have excellent bioavailability.
[Patent Literature]
(Patent Literature 1) Korean Laid-open Patent No.1997-006083
(Patent Literature 2) Korea Patent No. 10-0453179
[Non-Patent Literature]
(Non-Patent Literature 1) PDA J. Pharm. Sci. Tech. 2009 May-Jun:63(3):223-33
The present invention provides a combination drug capable of addressing problems with regard to formulation stability and bioavailability in a combination drug of ranitidine, bismuth subcitrate and sucralfate, and that has a simple preparation process and more comfortable for a patient to swallow.
According to research results of the inventors, the fact that, when a combination drug of ranitidine, bismuth subcitrate and sucralfate is prepared, if particle sizes of bismuth subcitrate and sucralfate are controlled, a moisture absorption of ranitidine is suppressed to achieve formulation stability, a physical interaction between drugs is prevented to achieve drug bioavailability without preparing a tablet-within-a-tablet was identified.
Specifically, in the following examples, a grinder or a mesh for each type was used to classify sucralfate and bismuth subcitrate for each particle size, a particle size was measured, sucralfate and bismuth subcitrate classified for each size were used and mixed with ranitidine, and then a moisture content, formulation stability and bioavailability of ranitidine were observed. As a result, it was confirmed that a moisture content of ranitidine was suppressed in a specific particle size range of sucralfate and bismuth subcitrate, formulation stability was maintained, and drug bioavailability was excellent. Then, the size was selected as an optimum particle size.
Therefore, the present invention provides a pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients, and satisfies at least one of the following conditions:
(a) sucralfate has an average particle size of 1 to 25 ㎛,
(b) bismuth subcitrate has an average particle size of 5 to 90 ㎛.
In the pharmaceutical composition of the present invention, the sucralfate may have an average particle size of 1 to 25 ㎛, for example, 1 to 20 ㎛, 2 to 25 ㎛, 2 to 20 ㎛, 2 to 15 ㎛, 3 to 15 ㎛, 2 to 10 ㎛, 3 to 10 ㎛, 3 to 8 ㎛, 4 to 10 ㎛, or 4 to 8 ㎛.
In the pharmaceutical composition of the present invention, the bismuth subcitrate may have an average particle size of 5 to 90 ㎛, for example, 5 to 80 ㎛, 5 to 75 ㎛, 5 to 70 ㎛, 10 to 75 ㎛, 10 to 60 ㎛, 10 to 50 ㎛, 15 to 75 ㎛, 20 to 75 ㎛, 25 to 70 ㎛, 25 to 65 ㎛, 25 to 60 ㎛, 25 to 55 ㎛, or 25 to 50 ㎛.
In an embodiment, the sucralfate may have an average particle size of 2 to 25 ㎛, or 2 to 10 ㎛.
In an embodiment, the bismuth subcitrate may have an average particle size of 5 to 75 ㎛, 25 to 70 ㎛, or 25 to 50 ㎛.
In an embodiment, the sucralfate may have an average particle size of 1 to 25 ㎛, and the bismuth subcitrate may have an average particle size of 5 to 90 ㎛.
In another embodiment, the sucralfate may have an average particle size of 2 to 25 ㎛, and the bismuth subcitrate may have an average particle size of 5 to 75 ㎛.
In still another embodiment, the sucralfate may have an average particle size of 2 to 10 ㎛, and the bismuth subcitrate may have an average particle size of 25 to 70 ㎛.
Although not specified as specific examples, when sucralfate and bismuth subcitrate having an average particle size within the above-exemplified range are combined and used, it is possible to obtain a pharmaceutical composition that is an object of the present invention.
In this specification, the average particle size is an average of a volume or a mass, and refers to a volume weighted Mean D[4,3] value with respect to a weight of a distribution.
When a particle size of a drug needs to be micronized, a general mill capable of micronizing particles such as a Z-mill, a hammer mill, a ball mill, a fluid energy mill or the like may be used for grinding. Also, when a sieve method that is performed using a sieve or a size classification method such as air current classification is used, it is possible to subdivide a particle size of a drug. A method of regulating a desired particle size is well-known in the related art. For example, the following document: [Pharmaceutical dosage forms: volume 2, 2nd edition, Ed.: H.A.Lieberman, L.Lachman, J.B.Schwartz (Chapter 3: SIZE REDUCTION)] is referenced to.
In this specification, a particle size of a drug may be represented based on a particle size distribution such as d(X) = Y (here, X and Y are positive numbers). d(X) = Y refers to the fact that, when a particle size distribution of a drug obtained by measuring a particle diameter of a certain drug in a formulation is represented as a cumulative curve, a point at which particle sizes accumulate in ascending order and the result reaches X% (% is calculated based on a number, a volume or a weight) has a particle diameter of Y. For example, d(10) represents a diameter of a particle at a point at which particle sizes of a drug accumulate in ascending order and the result reaches 10%. d(50) represents a diameter of a particle at a point at which particle sizes of a drug accumulate in ascending order and the result reaches 50%. d(90) represents a diameter of a particle at a point at which particle sizes of a drug accumulate in ascending order and the result reaches 90%.
In this specification, d(X) is alternatively represented as d(0.X), and d(X) and d(0.X) are interchangeable. For example, d(50) is represented as d(0.5), and d(10) and d(90) are represented as d(0.1) and d(0.9), respectively.
A number, a volume, or a weight that is used as a reference when the particle size distribution d(X) represents a percent with respect to total accumulated particles is changed according to a method that is used to measure a particle size distribution. The method of measuring the particle size distribution and a type of % related thereto are known in the related art. For example, when a well-known laser diffraction method is used to measure the particle size distribution, an X value of d(X) represents a percent calculated according to a volume average. It is well-known by those skilled in the art that the particle size distribution measurement result obtained by a specific method may have a correlation with results obtained from other techniques based on experiences through general experiments. For example, in the laser diffraction method, a volume average particle size is provided to correspond to a volume of a particle, which corresponds to a weight average particle size when a density is constant.
In the present invention, in order to measure an average particle size and a particle size distribution of particles of bismuth subcitrate and sucralfate, a commercially available device using a laser diffraction and scattering method based on a Mie theory may be used. For example, a commercially available device such as a Mastersizer laser diffraction device of Malvern Instruments may be used for measurement. This device is used to obtain a particle diameter distribution such that, when a helium-neon laser beam is emitted toward or a blue light emitting diode emits light toward particles, scattering is caused, a light scattering pattern is shown in a detector, and this light scattering pattern is analyzed according to the Mie theory. Any of dry and wet methods may be used as the measurement method, but results measured by the wet method are shown in the following examples.
In an embodiment, the pharmaceutical composition of the present invention may have a particle size distribution of sucralfate that additionally satisfies at least one of the following conditions.
1) d(10) is 1 to 10 ㎛,
2) d(50) is 3 to 25 ㎛,
3) d(90) is 5 to 50 ㎛.
In an embodiment, the pharmaceutical composition of the present invention may have a particle size distribution of bismuth subcitrate that additionally satisfies at least one of the following conditions.
1) d(10) is 5 to 17 ㎛,
2) d(50) is 20 to 70 ㎛,
3) d(90) is 40 to 130 ㎛.
In another embodiment, the pharmaceutical composition of the present invention may have a particle size distribution of sucralfate that additionally satisfies at least one of the following conditions:
1) d(10) is 1 to 10 ㎛,
2) d(50) is 3 to 25 ㎛,
3) d(90) is 5 to 50 ㎛; and
a particle size distribution of bismuth subcitrate may satisfy at least one of the following conditions:
1) d(10) is 5 to 17 ㎛,
2) d(50) is 20 to 70 ㎛,
3) d(90) is 40 to 130 ㎛.
Unlike sucralfate and bismuth subcitrate whose average particle sizes or particle size distributions are preferably within a specific range, a particle size of ranitidine included in the pharmaceutical composition of the present invention is not particularly limited.
The present invention also provides a pharmaceutical composition in which sucralfate and bismuth subcitrate whose average particle size or particle size distribution are within the above range, and sucralfate has a dissolution rate whose level is equivalent to a dissolution rate of sucralfate of AlbisTM Tablet. Here, the guidelines for drug equivalence test control may be used to determine whether the dissolution rate shows an equivalent level.
The present invention also provides a pharmaceutical composition in which sucralfate and bismuth subcitrate whose average particle sizes or particle size distributions are within the above range, and ranitidine and bismuth subcitrate show an area under the concentration-time curve (AUC) and a maximum observed plasma concentration (Cmax) of a bioequivalence level, compared to AlbisTM Tablet having the same active ingredient dose. Here, drug equivalence criteria may be used to determine whether the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (Cmax) show a bioequivalence level. For example, when the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (Cmax) of a reference drug and a test drug are log-transformed and statistically processed according to a bioequivalence test of drug equivalence test criteria of drug-related law, if two items are within log 0.8 to log 1.25 in a confidence interval of 90% of a difference of log-transformed average values, it is determined that the drug equivalence test is equivalent. However, as the guidelines for bioequivalence exception, it was determined as equivalent when both conditions are satisfied, 1) when a difference of log-transformed average values of comparison evaluation item values of the reference drug and the test drug is within log 0.9 to log 1.11, and 2) when a comparison dissolution test is performed according to drug equivalence test criteria, the results are equivalent under all defined conditions.
Meanwhile, contents of ranitidine, sucralfate and bismuth subcitrate, which are active ingredients of the pharmaceutical composition of the present invention, may be included at a composition ratio of 1 to 2 parts by weight of ranitidine, 6 to 12 parts by weight of sucralfate, and 2 to 4 parts by weight of bismuth subcitrate to be pharmacologically effectively functioned.
Specifically, the pharmaceutical composition of the present invention is preferably prepared to comprise ranitidine at 50 to 300 mg, sucralfate at 240 to 1200 mg, and bismuth subcitrate at 80 to 400 mg, and particularly preferably prepared to include ranitidine at 50 to 150 mg, sucralfate at 240 to 600 mg, and bismuth subcitrate at 80 to 200 mg.
The pharmaceutical composition of the present invention comprises at least one excipient other than the active ingredients.
A diluent increases a volume of a solid pharmaceutical composition, and enables for a patient and a caregiver to handle more easily a pharmaceutical dosage form including the composition. Exemplary diluents for the solid composition include microcrystalline cellulose (for example, Avicel®), microfine cellulose, lactose, a starch, a pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrate, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, a magnesium oxide, maltodextrin, mannitol a polymethacrylate (for example, Eudragit®), calcium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
The solid pharmaceutical composition compressed in a dosage form such as a tablet may comprise an excipient that helps the active ingredient to be bound to another excipient after compression. Binders for the solid pharmaceutical composition include acacia, alginic acid, a carbomer (for example, a carbopol), sodium carboxymethylcellulose, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxy ethylcellulose, hydroxypropyl cellulose (for example, Klucel®), hydroxypropylmethylcellulose (for example, Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, a polymethacrylate, povidone (for example, Kollidon® and Plasdone®), a pregelatinized starch, sodium alginate and a starch.
When a disintegrant is added to the composition, it is possible to increase a dissolution rate of the compressed solid pharmaceutical composition in the patient's stomach. The disintegrant includes hydroxypropylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium (for example, Ac-Di-Sol®, Primellose®), microcrystalline cellulose, methylcellulose, powdered cellulose, colloidal silicon dioxide, croscarmellose sodium, crospovidone (for example, Kollidon® and Polyplasdone®), guar gum, magnesium aluminum silicate, polacrilin potassium, a pregelatinized starch, alginic acid, sodium alginate, sodium starch glycolate (for example, Explotab®) and a starch.
When a powder composition is compressed to prepare a dosage form such as a tablet, the composition receives a pressure from a punch and a dye. Some excipients and active ingredients tend to adhere to a surface of the punch and the dye, which may cause pitting and other surface irregularity in products. In order to decrease adhesiveness and easily extract a product material from the dye, a lubricant may be added to the composition. The lubricant includes stearate salts such as magnesium stearate, calcium stearate, aluminum stearate and zinc stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, a polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, talc and the like.
In order to increase storage stability, storage and chelate formulations such as alcohol, sodium benzoate, butylated hydroxytoluene, butylated hydroxyanisole and ethylenediaminetetraacetic acid may be added at a safe intake level.
The pharmaceutical composition of the present invention is not limited thereto, but may be formulated as a tablet.
In an embodiment, the pharmaceutical composition of the present invention may be formulated as a matrix tablet. According to the following example, the pharmaceutical composition of the present invention is not formulated as a tablet-within-a-tablet containing a core tablet, but is formulated as a matrix tablet after particle sizes of sucralfate and bismuth subcitrate are controlled. Nevertheless, it was confirmed that all problems of a combination formulation in the related art were solved.
A tablet comprising the pharmaceutical composition according to the present invention may be additionally coated with a coating agent.
An embodiment of the present invention provides a tablet in which an uncoated tablet comprising ranitidine, sucralfate, and bismuth subcitrate as active ingredients is coated with a polyvinyl alcohol.
In the following example, it was confirmed that coating is performed using a polyvinyl alcohol as a coating agent, and more excellent stability can be ensured.
A process of formulating the pharmaceutical composition according to the present invention will be exemplified as follows.
Granules are prepared at a mixing ratio of 150:600:200 of ranitidine, sucralfate and bismuth. Here, as a binder, hydroxypropylmethylcellulose, hydroxypropylcellulose, a polyvinylpyrrolidone and the like may be used as other binders. Also, in the preparation method of the present invention, drying is preferably performed at a temperature of 30 to 60 ℃ such that a moisture content of a granule composition becomes 11% or less with respect to a total weight, and drying is most preferably performed at a temperature of 50 ℃.
The present invention provides a method of treating gastrointestinal diseases comprising administering the pharmaceutical composition comprising ranitidine, sucralfate and bismuth subcitrate having the above-exemplified particle size range as active ingredients to a subject in need thereof, and a use of the composition comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients to prepare a drug for treating gastrointestinal diseases.
In the present invention, the term "gastrointestinal diseases" include all symptoms or diseases such as inflammation and ulcer that occur in a digestive organ. For example, gastrointestinal diseases include stomach ulcers, gastritis, duodenal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, medication before anesthesia (prevention Mendelson's syndrome), post-op ulcer, and gastroduodenal ulcer due to nonsteroidal anti-inflammatory drugs (NSAIDs), but the present invention is not limited thereto.
In the present invention, the term "subject" refers to a warm-blooded animal such as a mammal suffering from specific diseases, disorders or diseases, and includes, for example, a human, an orangutan, a chimpanzee, a mouse, a rat, a dog, a cow, a chicken, a pig, a goat, a sheep and the like, but the present invention is not limited thereto.
In the present invention, the term "treatment" or "treating" includes alleviating symptoms, temporarily or permanently removing causes of symptoms, prevention or slowdown of occurrence of symptoms and progress of diseases, disorders or illness, but the present invention is not limited thereto.
An effective dose of the active ingredient of the pharmaceutical composition of the present invention refers to an amount that is necessary to treat diseases. Therefore, the effective dose may be regulated according to various factors such as type of disease, severity of disease, type and contents of an active ingredient and other components contained in the composition, types of dosage forms, a patient's age, weight, general health condition, and gender, diet, an administration time, an administration route, a releasing rate of the composition, a treatment period, and a drug used at the same time. For example, the pharmaceutical composition of the present invention may be administered once to three times a day, and a dose of 50 to 150 mg based on ranitidine may be administered once, but the present invention is not limited thereto.
According to the present invention, it is possible to prepare a combination drug that can address problems of hygroscopicity of ranitidine and formulation stability and has a simple preparation process and excellent bioavailability, by controlling particle sizes of sucralfate and bismuth subcitrate when the combination drug of ranitidine, sucralfate and bismuth subcitrate is prepared.
FIGS. 1 and 2 show change of average concentration of bismuth subcitrate in plasma of subjects to which tablets of Preparation Examples 12, 15 and 16 and Preparation Examples 14 and 17 are administered. FIG. 2 shows the enlarged FIG. 1.
FIGS. 3 to 5 show change of average concentration of ranitidine in plasma of subjects to which tablets of Preparation Examples 12, 15 and 16 are administered.
Advantages and features of the present invention and methods of achieving the same will be clearly understood with reference to the following detailed examples. However, the present invention is not limited to the examples to be disclosed below, but may be implemented in various different forms. The examples are provided in order to fully explain the present invention and fully explain the scope of the present invention for those skilled in the art. The scope of the present invention is defined by the appended claims.
[Examples]
Example 1: Regulation of particle sizes of sucralfate and bismuth subcitrate
Ranitidine, sucralfate and bismuth subcitrate having a raw material particle size before micronization of Table 1 were used for experiments.
Raw material particle size before micronization
Particle size distribution Ranitidine Sucralfate Bismuth subcitrate
d(10) 2.59 ㎛ 21.172 ㎛ 18.565 ㎛
d(50) 8.55 ㎛ 75.135 ㎛ 72.380 ㎛
d(90) 20.74 ㎛ 176.62 ㎛ 195.559 ㎛
Average 10.54 ㎛ 89.154 ㎛ 95.563 ㎛
The raw material particle size was measured using a particle size measurement device (Malvern Mastersizer 2000/Hydro S) according to a wet method under the following conditions.
<Particle size distribution measurement conditions>
Device: laser diffractive particle size distribution measurement device Malvern Mastersizer 2000/Hydro S(Malvern)
Wet unit: Hydro 2000S
Sample amount used: 1 g
Sample refractive index: 1.520
Sample measurement time: 10 seconds
Background measurement time: 10 seconds
Analysis model: General purpose
Calculation sensitivity: Normal
Particle shape: Irregular
Analysis range: 0.020 to 2000 ㎛
Ranitidine was then directly used for experiments without specific particle size regulation.
Sucralfate and bismuth subcitrate were micronized using the Z-mill and the grinder or using a mesh in order to regulate particle sizes.
After micronization, according to the average particle size and the particle size distribution, raw materials of sucralfate and bismuth subcitrate were classified as sucralfates 1 to 6 and bismuth subcitrates 1 to 5, and described in the following Tables 2 and 3.
Particle size distribution of sucralfate before and after micronization
Particle size distribution Sucralfate 1 (before micronization) Sucralfate 2 Sucralfate 3 Sucralfate 4 Sucralfate 5 Sucralfate 6
d(10) 21.172 ㎛ 12.355 ㎛ 10.302 ㎛ 6.052 ㎛ 3.269 ㎛ 1.727 ㎛
d(50) 5.135 ㎛ 32.169 ㎛ 29.961 ㎛ 20.339 ㎛ 9.275 ㎛ 3.901 ㎛
d(90) 176.62 ㎛ 63.957 ㎛ 54.248 ㎛ 39.574 ㎛ 19.441 ㎛ 8.116 ㎛
Average 89.154 ㎛ 35.395 ㎛ 29.122 ㎛ 23.657 ㎛ 12.664 ㎛ 4.517 ㎛
Particle size distribution of bismuth subcitrate before and after micronization
Particle size distribution Bismuth subcitrate 1 (before micronization) Bismuth subcitrate 2 Bismuth subcitrate 3 Bismuth subcitrate 4 Bismuth subcitrate 5
d(10) 18.565 ㎛ 14.533 ㎛ 12.269 ㎛ 11.582 ㎛ 0.786 ㎛
d(50) 72.380 ㎛ 67.703 ㎛ 39.756 ㎛ 26.387 ㎛ 4.264 ㎛
d(90) 195.559 ㎛ 122.137 ㎛ 77.674 ㎛ 48.833 ㎛ 9.547 ㎛
Average 95.563 ㎛ 68.068 ㎛ 42.698 ㎛ 28.455 ㎛ 4.824 ㎛
A formulation comprising ranitidine, sucralfate and bismuth subcitrate having different raw material particle size combinations was prepared to select a particle size of a drug that can ensure formulation stability, and an appropriate dissolution rate and bioavailability of the drug.
Therefore, in the following experimental examples, raw materials having different particle size combinations were used and formulated according to compositions of Table 4, and then experiments were performed.
Composition (wt%) of tablet comprising ranitidine, sucralfate and bismuth subcitrate
Classification Content
Ranitidine 12.2
Sucralfate 49.0
Bismuth subcitrate 16.3
Microcrystalline cellulose 13.0
Hydroxypropylcellulose 2.0
Croscarmellose sodium 5.0
Magnesium stearate 2.5
Total 100.0
Experimental Example 1: Regulation of particle size of sucralfate
In order to identify a dissolution rate change of sucralfate according to particle size regulation of sucralfate, as shown in Table 5, raw materials having a particle size combination in which only a particle size of sucralfate was changed while particle sizes of ranitidine and bismuth subcitrate were fixed were used and formulated according to compositions of Table 4 and then experiments were performed.
Particle size combination of ranitidine, sucralfate and bismuth subcitrate
Classification Ranitidine Sucralfate Bismuth subcitrate
Preparation Example 1 Non-micronized ranitidine sucralfate 1 bismuth subcitrate 3
Preparation Example 2 sucralfate 2
Preparation Example 3 sucralfate 3
Preparation Example 4 sucralfate 4
Preparation Example 5 sucralfate 5
Preparation Example 6 sucralfate 6
According to the same composition as described in Table 4 except that raw materials had different particle sizes, dry granules or wet granules according to a general method were prepared using purified water (or a mixed solvent of purified water and ethanol), dried at 50 ℃, and then established as an 18 mesh. Then, the prepared granules were tableted and coated to prepare a matrix tablet. Coating was performed with 3% PVA. Finally, a yellowish green rectangular film-coated tablet was obtained.
The tablets of Preparation Examples 1 to 6 were used to perform the comparison dissolution test of sucralfate. Since sucralfate is not absorbed in vivo, the bioequivalence test was not performed, but a comparison dissolution result was alternatively used. As the reference drug, AlbisTM Tablet (commercially available from Daewoong pharmaceutical Co., Ltd.) was used. The comparison dissolution test was performed according to Article 3, Section 1, No 1 (the guidelines for drug equivalence test control). A dissolution solution having a pH of 1.2 was used. According to the Korean Pharmacopeia Guideline of dissolution testing (the second method (paddle method)), an HPLC method was performed at a dissolution solution temperature of 37±0.5 ℃ and 50 rpm for 2 hours.
# Dissolution device
- Manufacturer: VARIAN
- Model name: VK7025 Vk8000
#HPLC analysis method
- HPLC equipment: Waters
- Analytical column: Aminopropylsilyl silica gel (4.6 x 250 mm, 5 ㎛)
- Mobile phase: buffer solution : acetonitrile = 9 : (filter using a membrane filter of 0.45 ㎛)
(buffer solution: 79.3 g of ammonium sulfate was obtained, 1000 mL of water was input, and then pH was regulated to 3.5 with phosphoric acid)
- Column temperature: 25 ℃
- Flow rate: 1.0 ml/min
- Detector: differential refractometer
- Injection volume: 50 ml
Sucralfate comparison dissolution test results
Classification/time(min) Dissolution rate (%)
5 10 15 30 45 60 90 120
Reference drug 3.4±2.1 31.2±4.2 45.2±3.8 64.2±3.2 72.3±3.0 79.6±2.4 86.2±2.1 91.2±1.0
Preparation Example 1 0.8±0.1 5.4±1.1 11.3±1.2 30.1±1.8 43.1±1.2 55.7±0.8 62.4±0.6 68.4±0.4
Preparation Example 2 1.1±0.2 12.1±1.0 25.3±0.6 42.6±1.9 55.2±1.5 66.5±0.9 72.4±1.7 76.1±1.2
Preparation Example 3 1.5±1.2 13.9±0.6 28.3±1.1 47.2±1.6 59.4±1.0 70.2±0.6 74.9±1.2 79.7±0.8
Preparation Example 4 2.0±1.4 21.2±0.9 35.4±0.5 53.7±1.6 67.5±1.1 76.0±1.0 81.4±1.5 85.6±0.7
Preparation Example 5 2.6±0.9 26.4±0.8 42.5±0.7 57.0±1.1 70.3±1.0 80.1±1.2 85.4±1.8 90.0±0.9
Preparation Example 6 2.1±1.0 33.4±0.8 48.2±1.1 63.4±1.2 75.2±0.8 83.2±0.1 88.3±1.1 92.4±0.7
The comparison dissolution test was performed as described above. As a result, as shown in Table 6, it was confirmed that the tablets of Preparation Examples 4 to 6 in which sucralfates having particle sizes represented as sucralfates 4 to 6 were used showed a dissolution rate of sucralfate that is equivalent to that of the reference drug. As equivalence determination criteria, when comparison is performed according to Article 21, Section 1 (the guidelines for drug equivalence test control), if an average dissolution rate of the reference drug is 85% or more within a defined test time and an average dissolution rate of a test drug at two time points at which an average dissolution rate of the reference drug is about 40% and 85% is within ±15% of the average dissolution rate of the reference drug, it was determined as equivalent.
Experimental Example 2: Regulation of particle size of bismuth subcitrate
Based on the results of Experimental Example 1, it was determined that raw materials having particle sizes represented as sucralfates 4 to 6 of Table 2 were preferably used as sucralfate. Therefore, a particle size of sucralfate was fixed to a particle size of "sucralfate 6" and then a particle size of bismuth subcitrate was regulated to evaluate stability of a tablet according to the particle size of bismuth.
Raw materials having particle size combinations of Table 7 were used and formulated according to compositions of Table 4, and then experiments were performed.
Particle size combination of ranitidine, sucralfate and bismuth subcitrate
Classification Ranitidine Sucralfate Bismuth subcitrate
Preparation Example 7 Non-micronized ranitidine of Table 1 sucralfate 6 bismuth subcitrate 1
Preparation Example 8 bismuth subcitrate 2
Preparation Example 9 bismuth subcitrate 3
Preparation Example 10 bismuth subcitrate 4
Preparation Example 11 bismuth subcitrate 5
According to the same composition as described in Table 4 except that raw materials had different particle sizes, ranitidine, sucralfate and bismuth subcitrate were prepared to dry granules or wet granules according to a general method using purified water (or a mixed solvent of purified water and ethanol), dried at 50 ℃ and then established as an 18 mesh. Then, the prepared granules were tableted and prepared as a matrix tablet, and room temperature stability was evaluated.
As a result, as shown in Table 8, it was confirmed that a property and a moisture content were satisfactory in specific particle sizes as in Preparation Examples 8, 9, and 10. This means that a problem in that a physical property of ranitidine is changed due to bismuth subcitrate when ranitidine is mixed with bismuth subcitrate is addressed, which is considered to be caused by the fact that an physical interaction between drugs is suppressed at a specific particle size.
Room temperature stability test results of a combination drug of ranitidine, sucralfate and bismuth subcitrate
Test item Classsification Criteria Initial Room temperature stability
1 month 3 months 6 months
Property Preparation Example 7 rectangular uncoated tablet appropriate appropriate appropriate inappropriate
Preparation Example 8 appropriate appropriate appropriate appropriate
Preparation Example 9 appropriate appropriate appropriate appropriate
Preparation Example 10 appropriate appropriate appropriate appropriate
Preparation Example 11 appropriate appropriate appropriate inappropriate
Moisture content Preparation Example 7 11% or less 9.11% 11.44% 14.22% -
Preparation Example 8 9.31% 9.92% 10.47% 10.90%
Preparation Example 9 8.91% 9.32% 10.07% 10.84%
Preparation Example 10 9.12% 9.72% 10.26% 10.74%
Preparation Example 11 8.55% 10.90% 13.22% -
It was observed that particle size combinations of formulations of Preparation Examples 8, 9, and 10 addressed problems in that a physical property of ranitidine is changed due to bismuth subcitrate. In order to additionally check whether the combinations are appropriate in aspects of formulation stability, moisture absorption and bioavailability, experiments were then performed.
Experimental Example 3: Comparison stability test for selecting coating agent
Based on the uncoated tablet of Preparation Example 9, in order to prevent an additional moisture content of ranitidine, a test for selecting a coating agent was performed. The uncoated tablet of Preparation Example 9 was coated with a polyvinyl alcohol (PVA) (Preparation Example 12), and HPMC (Preparation Example 13) (3 wt% for the uncoated tablet). Then, a room temperature stability test of the coated tablets was performed. As a result, it was confirmed that both two samples had appropriate properties, but the tablet of Preparation Example 12 coated with PVA had no significant change in a moisture content test and showed an excellent moisture-proof effect.
Comparison stability test results for selecting coating agent
Test item Classification Criteria Initial Room temperature stability
1 month 3 months 6 months
Property Preparation Example 12 rectangular film-coated tablet appropriate appropriate appropriate appropriate
Preparation Example 13 appropriate appropriate appropriate appropriate
Moisture content Preparation Example 12 11% or less 9.30% 9.45% 9.44% 9.51%
Preparation Example 13 9.44% 11.19% 14.14% 16.92%
Based on the test performed as described above, PVA was selected as the coating agent, and the uncoated tablets of Preparation Examples 7, 8, 10, and 11 were coated with 3 wt% PVA to prepare coated tablets of Preparation Examples 14, 15, 16, and 17. Then, these coated tablets were used to perform the following experimental examples.
Experimental Example 4: Evaluation of formulation stability
A room temperature/accelerated stability test was performed on the coated tablets of Preparation Examples 12, 14, 15, 16 and 17. The results are shown in Table 10. It was observed that the property and content disintegration tests of the tablets of Preparation Examples 12, 15 and 16 had results that were appropriate with respect to criteria. In Preparation Examples 14 and 17, a property was inappropriate and thus the following content and disintegration tests were stopped.
Room temperature/accelerated stability test results
Test item Classification Criteria Initial 1 month 3 months 6 months
accelerated room temperature accelerated room temperature accelerated
Property Preparation Example 12 yellowish green film-coated tablet appropriate appropriate appropriate appropriate appropriate appropriate
Preparation Example 14 appropriate appropriate appropriate inappropriate inappropriate inappropriate
Preparation Example 15 appropriate appropriate appropriate appropriate appropriate appropriate
Preparation Example 16 appropriate appropriate appropriate appropriate appropriate appropriate
Preparation Example 17 appropriate appropriate appropriate appropriate inappropriate inappropriate
Ranitidine Preparation Example 12 90.0 to 110.0% 100.20% 100.47% 100.54% 100.06% 100.72% 99.50%
Preparation Example 14 100.80% 99.45% 99.70% - - -
Preparation Example 15 100.47% 100.20% 100.26% 100.34% 99.80% 99.94%
Preparation Example 16 99.28% 100.41% 99.20% 99.45% 99.52% 99.64%
Preparation Example 17 99.10% 99.81% 98.50% 99.48% - -
Sucralfate Preparation Example 12 90.0 to 110.0% 101.40% 101.22% 101.52% 101.70% 101.20% 100.19%
Preparation Example 14 100.10% 101.59% 101.82% - - -
Preparation Example 15 99.87% 99.94% 100.10% 99.93% 100.31% 99.91%
Preparation Example 16 102.33% 101.50% 101.76% 101.80% 101.24% 101.92%
Preparation Example 17 100.22% 100.86% 100.30% 100.90% - -
Bismuth Preparation Example 12 90.0 to 110.0% 99.90% 98.50% 99.93% 99.56% 99.13% 99.72%
Preparation Example 14 99.10% 97.84% 99.77% - - -
Preparation Example 15 101.38% 100.99% 100.84% 100.68% 100.44% 100.38%
Preparation Example 16 100.80% 100.37% 100.58% 99.80% 99.76% 99.84%
Preparation Example 17 100.20% 98.85% 98.86% 99.33% - -
Disintegration test Preparation Example 12 Within 30 minutes 9 minutes 9 minutes 10 minutes 9 minutes 9 minutes 9 minutes
Preparation Example 14 10 minutes 10 minutes 10 minutes - - -
Preparation Example 15 9 minutes 9 minutes 10 minutes 9 minutes 10 minutes 9 minutes
Preparation Example 16 9 minutes 9 minutes 9 minutes 10 minutes 9 minutes 9 minutes
Preparation Example 17 8 minutes 8 minutes 8 minutes 9 minutes - -
Experimental Example 5: Change in moisture content in formulation according to particle size of drug
The coated tablets of Preparation Examples 12, 14, 15, 16 and 17 were used to perform a moisture content test as follows. The test was performed at room temperature for 6 months. In order to measure a moisture content, a Karl Fisher method among general test methods according to the Korean Pharmacopeia Guideline was used as a moisture measurement method. Using the fact that water is quantitatively reacted with iodine and sulfur dioxide in the presence of low level alcohol such as methanol and an organic base such as pyridine, methanol for moisture measurement was used as a reagent used for a moisture measurement method. A sample was obtained by grinding a tablet and about 200 mg thereof was used for the test.
Moisture content test results of coated tablets
Test item Classification Criteria Initial Room temperature stability
1 month 3 months 6 months
Moisture content Preparation Example 12 11% or less 9.16% 9.11% 9.23% 9.30%
Preparation Example 14 9.17% 10.05% 10.92% -
Preparation Example 15 10.22% 9.80% 9.97% 10.11%
Preparation Example 16 8.49% 8.88% 8.67% 8.90%
Preparation Example 17 9.35% 10.01% 10.75% -
As can be seen in the results of Table 11, tablets of Preparation Examples 12, 15 and 16 were appropriate for moisture content criteria. However, the tablets of Preparation Examples 14 and 17 had an inappropriate property in the room temperature stability test for 6 months, and thus an additional moisture test was not performed. Based on such results, it was confirmed that a moisture content of ranitidine was suppressed due to particle sizes of sucralfate and bismuth subcitrate, and a more excellent stability of a product through PVA coating can be confirmed.
Experimental Example 6: PK test results according to a difference of particle sizes
The coated tablets of Preparation Examples 12, 14, 15, 16 and 17 were used to perform a PK test on healthy subjects. With respect to log-transformed values of two comparison evaluation items of AUC and Cmax, analysis of variance was performed with bismuth subcitrate and ranitidine.
As drug equivalence criteria, when the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (Cmax) of a reference drug and a test drug are log-transformed and statistically processed according to a bioequivalence test of drug equivalence test criteria of drug-related law, if two items are within log 0.8 to log 1.25 in a confidence interval of 90% of a difference of log-transformed average values, it is determined that the drug equivalence test is equivalent. However, as the guidelines for bioequivalence exception, it was determined as equivalent when both conditions are satisfied, 1) when a difference of log-transformed average values of comparison evaluation item values of the reference drug and the test drug is within log 0.9 to log 1.11, and 2) when a comparison dissolution test is performed according to drug equivalence test criteria, the results are equivalent under all defined conditions.
AlbisTM Tablet (commercially available from Daewoong pharmaceutical Co., Ltd.) was used as the reference drug.
FIGS. 1 and 2 are comprehensive graphs that statistically show bioavailability parameters of the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (Cmax) of bismuth subcitrate obtained from blood drug concentration data of subjects to which the tablets of Preparation Example 12, 14, 15, 16 and 17 were administered. FIGS. 3 to 5 are graphs that statistically show bioavailability parameters of the area under the concentration-time curve (AUC) and the maximum observed plasma concentration (Cmax) of ranitidine obtained from blood drug concentration data of subjects to which the tablets of Preparation Examples 12, 15 and 16 were administered. In the tablets of Preparation Examples 12, 15 and 16 and the tablets of Preparation Examples 14 and 17, particle sizes of ranitidine and sucralfate were the same, an excipient and a coating agent were also the same, but only a particle size of bismuth subcitrate was different. Based on PK test results of FIGS. 1 and 2, it can be confirmed that bioavailability differs according to a particle size of bismuth subcitrate. That is, it is possible to identify an interval in which bismuth subcitrate has appropriate bioavailability through a particle size, and it can be confirmed that bioavailability of ranitidine that was additionally tested was also equivalent.
PK test results of the tablet of Preparation Example 12 were compared with PK test results of the reference drug. As a result, in bismuth subcitrate, AUC was 0.8749 to 1.1967, and Cmax was 0.8681 to 1.12342. Therefore, it was confirmed that PK was equivalent. In ranitidine, AUC was 0.9282 to 1.1213, Cmax was 0.9282 to 1.1539, and thus it was also equivalent.
Based on PK test results of the tablet of Preparation Example 15, in bismuth subcitrate, AUC was 0.7672 to 1.1624 and Cmax was 0.7717 to 1.1633. Since a lower limit was inappropriate, PK was non-equivalent. However, equivalence was confirmed according to the guidelines for equivalence exception. In ranitidine, AUC was 0.9029 to 1.0108, Cmax was 0.8151 to 1.0280, and thus it was equivalent.
Based on PK test results of the tablet of Preparation Example 16, in bismuth subcitrate, AUC was 1.1058 to 1.2785 and Cmax was 1.0545 to 1.3188. An upper limit was inappropriate and thus PK was non-equivalent. However, equivalence was confirmed according to the guidelines for bioequivalence exception. In Ranitidine, AUC was 0.9085 to 1.0084, Cmax was 0.8912 to 1.0411, and thus it was equivalent.
Meanwhile, based on PK test results of the tablet of Preparation Example 14, in bismuth subcitrate, AUC was 0.5906 to 0.7805, and Cmax was 0.4538 to 0.6794. Since a lower limit was inappropriate, PK was non-equivalent.
Meanwhile, based on PK test results of the tablet of Preparation Example 17, in bismuth subcitrate, AUC was 1.8565 to 2.7649, and Cmax was 2.0868 to 3.1544. Since an upper limit is inappropriate, PK was non-equivalent.
As a result, it was confirmed that the tablets of Preparation Examples 12, 15 and 16 suppressed a moisture content of ranitidine by appropriately regulating particle sizes of sucralfate and bismuth subcitrate and can be used as a combination drug of suppressing a change in a physical property due to drug mixing, and providing excellent bioavailability.

Claims (19)

  1. A pharmaceutical composition for treating gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active ingredients, and satisfying at least one of the following conditions:
    (a) the sucralfate has an average particle size of 1 to 25 ㎛,
    (b) the bismuth subcitrate has an average particle size of 5 to 90 ㎛.
  2. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has an average particle size of 2 to 25 ㎛.
  3. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has an average particle size of 2 to 10 ㎛.
  4. The pharmaceutical composition according to claim 1,
    wherein the bismuth subcitrate has an average particle size of 5 to 75 ㎛.
  5. The pharmaceutical composition according to claim 1,
    wherein the bismuth subcitrate has an average particle size of 25 to 70 ㎛.
  6. The pharmaceutical composition according to claim 1,
    wherein the bismuth subcitrate has an average particle size of 25 to 50 ㎛.
  7. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has an average particle size of 1 to 25 ㎛, and the bismuth subcitrate has an average particle size of 5 to 90 ㎛.
  8. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has an average particle size of 2 to 25 ㎛, and the bismuth subcitrate has an average particle size of 5 to 75 ㎛.
  9. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has an average particle size of 2 to 10 ㎛, and the bismuth subcitrate has an average particle size of 25 to 70 ㎛.
  10. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has a particle size distribution that satisfies at least one of the following conditions:
    1) d(10) is 1 to 10 ㎛,
    2) d(50) is 3 to 25 ㎛,
    3) d(90) is 5 to 50 ㎛.
  11. The pharmaceutical composition according to claim 1,
    wherein the bismuth subcitrate has a particle size distribution that satisfies at least one of the following conditions:
    1) d(10) is 5 to 17 ㎛,
    2) d(50) is 20 to 70 ㎛,
    3) d(90) is 40 to 130 ㎛.
  12. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has a particle size distribution that satisfies at least one of the following conditions,
    1) d(10) is 1 to 10 ㎛,
    2) d(50) is 3 to 25 ㎛,
    3) d(90) is 5 to 50 ㎛, and
    wherein the bismuth subcitrate has a particle size distribution that satisfies at least one of the following condition:
    1) d(10) is 5 to 17 ㎛,
    2) d(50) is 20 to 70 ㎛,
    3) d(90) is 40 to 130 ㎛.
  13. The pharmaceutical composition according to claim 1,
    wherein the sucralfate has a dissolution rate whose level is equivalent to a dissolution rate of sucralfate of AlbisTM Tablet.
  14. The pharmaceutical composition according to claim 1,
    wherein the ranitidine and the bismuth subcitrate in the pharmaceutical composition show an area under the concentration-time curve (AUC) and a maximum observed plasma concentration (Cmax) of a bioequivalence level compared to AlbisTM Tablet having the same active ingredient dose.
  15. The pharmaceutical composition according to any of claims 1 to 14,
    wherein the pharmaceutical composition comprises ranitidine at 50 to 300 mg, sucralfate at 240 to 1200 mg and bismuth subcitrate at 80 to 400 mg.
  16. The pharmaceutical composition according to any of claims 1 to 14,
    wherein the pharmaceutical composition is formulated in the form of a tablet.
  17. The pharmaceutical composition according to any of claims 1 to 14,
    wherein the pharmaceutical composition is formulated in the form of a matrix tablet.
  18. The pharmaceutical composition according to claim 17,
    wherein the tablet is coated with a coating agent.
  19. The pharmaceutical composition according to claim 18,
    wherein the coating agent is a polyvinyl alcohol.
PCT/KR2016/000935 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases WO2016122226A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MYPI2017702737A MY195824A (en) 2015-01-30 2016-01-28 A Pharmaceutical Composition for Treating Gastrointestinal Diseases
EA201791458A EA032385B9 (en) 2015-01-30 2016-01-28 Pharmaceutical composition for treating gastrointestinal diseases
UAA201707833A UA116517C2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases
EP16743704.5A EP3250199A4 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases
MX2017007567A MX2017007567A (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases.
JP2017540683A JP6419347B2 (en) 2015-01-30 2016-01-28 Pharmaceutical composition for treatment of gastrointestinal diseases
CN201680007680.7A CN107205947B (en) 2015-01-30 2016-01-28 Pharmaceutical composition for treating gastrointestinal diseases
BR112017013857-3A BR112017013857B1 (en) 2015-01-30 2016-01-28 PHARMACEUTICAL COMPOSITION TO TREAT GASTROINTESTINAL DISEASES
CONC2017/0006222A CO2017006222A2 (en) 2015-01-30 2017-06-23 Pharmaceutical composition for the treatment of gastrointestinal diseases
PH12017550051A PH12017550051A1 (en) 2015-01-30 2017-07-25 A pharmaceutical composition for treating gastrointestinal diseases
SA517382016A SA517382016B1 (en) 2015-01-30 2017-07-29 A Pharmaceutical Composition for Treating Gastrointestinal Diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2015-0015339 2015-01-30
KR20150015339 2015-01-30
KR10-2015-0147513 2015-10-22
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases

Publications (2)

Publication Number Publication Date
WO2016122226A2 true WO2016122226A2 (en) 2016-08-04
WO2016122226A3 WO2016122226A3 (en) 2016-09-15

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX2017007567A (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
JP2021518422A (en) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ Pharmaceutical composition containing lenalidomide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
WO2000078307A1 (en) 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
KR20140072673A (en) 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81011T1 (en) * 1987-03-09 1992-10-15 Procter & Gamble COMPOSITIONS AND THEIR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
BR9507533A (en) * 1994-04-26 1997-09-02 Chugai Pharmaceutical Co Ltd Fused granulated sucralfate preparations and a process for their production
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio equipment
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
WO2010001930A1 (en) * 2008-07-01 2010-01-07 ライオン株式会社 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical composition for preventing or treating a gastroenteric disease comprising ilaprazole and a mixture of sucralfate and bismuth agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
WO2000078307A1 (en) 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
KR100453179B1 (en) 1999-06-21 2004-10-15 주식회사 대웅 Orally Administrable Pharmaceutical Preparation Having Therapeutic Effect on Gastrointestinal Disorders Comprising Coated Ranitidine, Bismuth Subcitrate and Sucralfate
KR20140072673A (en) 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"SIZE REDUCTION", vol. 2, article "Pharmaceutical dosage forms"
PDA J. PHARM. SCI. TECH., vol. 63, no. 3, May 2009 (2009-05-01), pages 223 - 33

Also Published As

Publication number Publication date
UA116517C2 (en) 2018-03-26
WO2016122226A3 (en) 2016-09-15
PH12017550051A1 (en) 2018-01-29
PE20171340A1 (en) 2017-09-13
CN107205947A (en) 2017-09-26
MY195824A (en) 2023-02-22
CN107205947B (en) 2020-05-22
EA032385B9 (en) 2019-07-31
BR112017013857A2 (en) 2018-02-27
EP3250199A2 (en) 2017-12-06
ECSP17038599A (en) 2017-09-29
CL2017001680A1 (en) 2018-01-12
EP3250199A4 (en) 2018-08-08
TWI635859B (en) 2018-09-21
KR101583452B1 (en) 2016-01-11
EA032385B1 (en) 2019-05-31
CO2017006222A2 (en) 2017-09-20
AR105413A1 (en) 2017-10-04
GEP20196941B (en) 2019-01-10
KR20160094268A (en) 2016-08-09
SA517382016B1 (en) 2021-03-18
KR101583452B9 (en) 2022-05-02
TW201639559A (en) 2016-11-16
MX2017007567A (en) 2017-10-19
JP2018503672A (en) 2018-02-08
JP6419347B2 (en) 2018-11-07
EA201791458A1 (en) 2017-11-30
MA41432A (en) 2017-12-05

Similar Documents

Publication Publication Date Title
WO2018070671A1 (en) Lenalidomide oral tablet composition
WO2020040438A1 (en) Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
WO2018021772A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2013058450A1 (en) Stabilized eperisone medical composition, and sustained-release preparation containing same
WO2018084627A2 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
WO2019004770A9 (en) Oral solid preparation composition comprising proton pump inhibitor, oral solid preparation comprising same, and preparation method therefor
WO2016122226A2 (en) A pharmaceutical composition for treating gastrointestinal diseases
WO2022103233A1 (en) Pharmaceutical composite formulation comprising rabeprazole and antacid, and preparation method therefor
WO2012148181A2 (en) Composition for the controlled-release of drugs
WO2019066555A1 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
WO2021101295A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
US20050031696A1 (en) Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
WO2012077968A2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2022071768A1 (en) A pharmaceutical composition comprising fenofibrate particles with improved bioavailability
WO2019107859A1 (en) Nano solubilized porous body with dutasteride encapsulated therein, pharmaceutical composition containing same and method of producing same
WO2015108392A1 (en) Small pharmaceutical tablet containing esomeprazole
WO2015147467A1 (en) Pharmaceutical preparation comprising telmisartan and (s)-amlodipine with improved oxidative stability
WO2022075760A1 (en) Pharmaceutical composition including apremilast
WO2019199133A1 (en) Orally administered coated tablet composition of lenalidomide
WO2019199132A1 (en) Lenalidomide oral tablet composition in various amounts
WO2021194253A1 (en) Oral tablet composition of pomalidomide and method for preparing same
WO2013032206A1 (en) Controlled-release oral composition containing itopride hydrochloride, and preparation method thereof
WO2019208967A1 (en) Enteric coated tablet comprising fenofibric acid or pharmaceutically acceptable salt thereof
WO2014142521A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US20140179712A1 (en) Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16743704

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/007567

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: NC2017/0006222

Country of ref document: CO

Ref document number: 001147-2017

Country of ref document: PE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017013857

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 14551

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 201791458

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12017550051

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2016743704

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017540683

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A201707833

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 112017013857

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170626